Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial

Miyaoka, Tsuyoshi, Kanayama, Misako, Wake, Rei, Hashioka, Sadayuki, Hayashida, Maiko, Nagahama, Michiharu, Okazaki, Shihoh, Yamashita, Satoko, Miura, Shoko, Miki, Hiroyuki, Matsuda, Hiroyuki, Koike, Masahiro, Izuhara, Muneto, Araki, Tomoko, Tsuchie, Keiko, Azis, Ilhamuddin Abdul, Arauchi, Ryosuke, Abdullah, Rostia Arianna, Oh-Nishi, Arata, Horiguchi, Jun · 2018 · Clinical Neuropharmacology

Abstract

Aim: Up to 60% of depressed patients do not obtain sufficient relief from a course of antidepressant therapy, and these treatment-resistant major depressive disorder (TRD) patients are at increased risk for relapse, chronicity, persistent psychosocial impairments, and suicide. Probiotics actively participate in treatment of neuropsychiatric disorders. However, the role of gut microbiota in brain disorders and depression remains unclear. We performed a prospective study to evaluate the effects of Clostridium butyricum MIYAIRI 588 (CBM588). Methods: This was an 8-week open-label study to evaluate the efficacy and safety of CBM588 in combination with antidepressants in adult patients diagnosed with TRD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Forty antidepressant-treated inpatients were included. Patients were randomized to adjuvant treatment with CBM588 (n = 20) or control (n = 20). The primary endpoint was the change in the 17-item Hamilton Depression Rating Scale score from baseline to week 8. Secondary end points were changes in the Beck Depression Inventory and the Beck Anxiety Inventory scale scores from baseline to week 8. The Systematic Assessment of Treatment Emergent Events—General Inquiry was used to assess adverse effects. Results: CBM588 (60 mg/d) in combination with antidepressants (flvoxamine, paroxetine, escitalopram, duroxetine, and sertraline) provided significant improvement in depression. All patients completed the trial, and 70% responded to treatment; the remission rate was 35.0%. No serious adverse events occurred. Conclusions: These preliminary data suggest that CBM588 in combination with antidepressants is effective and well tolerated in the treatment of TRD. Further studies using a larger, double-blind, parallel-group design are warranted to confirm these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/wnf.0000000000000299

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 26

  1. 2017, Can gut microbes play a role in mental disorders and their treatment?, Psychiatr Danub, 29, 28, 10.24869/psyd.2017.28 · DOI
  2. 2011, Gut microbiota and diabetes: from pathogenesis to therapeutic perspective, Acta Diabetol, 48, 257, 10.1007/s00592-011-0333-6 · DOI · Paper page
  3. 2013, Melancholic microbes: a link between gut microbiota and depression?, Neurogastroenterol Motil, 25, 713, 10.1111/nmo.12198 · DOI · Paper page
  4. 2009, Traumatic brain injury and intestinal dysfunction: uncovering the neuro-enteric axis, J Neurotrauma, 26, 1353, 10.1089/neu.2008.0858 · DOI · Paper page
  5. 2003, Alterations of intestinal mucosa structure and barrier function following traumatic brain injury in rats, World J Gastroenterol, 9, 2776, 10.3748/wjg.v9.i12.2776 · DOI · Paper page
  6. 2015, Bifidobacteria modulate cognitive processes in an anxious mouse strain, Behav Brain Res, 287, 59, 10.1016/j.bbr.2015.02.044 · DOI · Paper page
  7. 2015, Small intestine dysfunction in Parkinson's disease, J Neural Transm, 122, 1659, 10.1007/s00702-015-1442-0 · DOI
  8. 2006, Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy, J Clin Gastroenterol, 40, 264, 10.1097/00004836-200603000-00020 · DOI · Paper page
  9. 2009, Lactobacillus fermentum ME-3 — an antimicrobial and antioxidative probiotic, Microb Ecol Health Dis, 21, 1
  10. 1984, The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants, Microbiol Immunol, 28, 975, 10.1111/j.1348-0421.1984.tb00754.x · DOI · Paper page
  11. 1997, Intestinal distribution and intraluminal localization of orally administered Clostridium butyricum in rats, Microbiol Immunol, 41, 665, 10.1111/j.1348-0421.1997.tb01909.x · DOI
  12. 1999, Probiotic bacteria stimulate gut epithelial cell proliferation in rat, Dig Dis Sci, 44, 2119, 10.1023/A:1026647024077 · DOI
  13. 2001, Butyrate suppression of colonocyte NFκB activation and cellular proteasome activity, J Biol Chem, 276, 44641, 10.1074/jbc.M105170200 · DOI · Paper page
  14. 2007, Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action, J Pharmcol Experiment Therapeutics, 321, 892, 10.1124/jpet.107.120188 · DOI · Paper page
  15. 1980, Rating depressive patients, J Clin Psychiatry, 41, 21
  16. 1961, An inventory for measuring depression, Arch Gen Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page
  17. 1986, SAFTEE: a technique for the systematic assessment of side effects in clinical trials, Psychopharmcol Bull, 22, 343
  18. 2004, Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics, Curr Drug Targets, 5, 279, 10.2174/1389450043490514 · DOI
  19. 2005, Major depressive disorder: probiotics may be an adjuvant therapy, Med Hypotheses, 64, 533, 10.1016/j.mehy.2004.08.019 · DOI · Paper page
  20. 2007, Impact of consuming a milk drink containing a probiotic on mood and cognition, Eur J Clin Nutr, 61, 355, 10.1038/sj.ejcn.1602546 · DOI · Paper page
  21. 2008, Does minocycline have antidepressant effect?, Biomed Pharmacother, 62, 308, 10.1016/j.biopha.2007.12.005 · DOI
  22. 2007, Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates, J Neurosci, 27, 4894, 10.1523/JNEUROSCI.0237-07.2007 · DOI · Paper page
  23. 2007, What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?, Eur Arch Psychiatry Clin Neurosci, 257, 250, 10.1007/s00406-007-0728-0 · DOI · Paper page
  24. 2015, Neuroprotective effects of Clostridium butyricum against vascular dementia in mice via metabolic butyrate, Biomed Res Int, 41294, 12
  25. 2016, Clostridium butyricum attenuates cerebral ischemia/reperfusion injury in diabetic mice via modulation of gut microbiota, Brain Res, 1642, 180, 10.1016/j.brainres.2016.03.042 · DOI
  26. 2004, Escitalopram versus citalopram: the surprising role of the R-enantiomer, Psychopharmacology (Berl), 174, 163

Cited by

See all 186

Metadata

Authors
Miyaoka, T., Kanayama, M., Wake, R., Hashioka, S., Hayashida, M., Nagahama, M., Okazaki, S., Yamashita, S., Miura, S., Miki, H., Matsuda, H., Koike, M., Izuhara, M., Araki, T., Tsuchie, K., Azis, I. A., Arauchi, R., Abdullah, R. A., Oh-Nishi, A., & Horiguchi, J.
Venue
Clinical Neuropharmacology
Published
2018-09
Volume
41
Issue
5
Pages
151-155
ISSN
  • 0362-5664 (ISSN-L)
  • 1537-162X
OpenAlex
W2895770947
Cited by
186
References
16
FWCI
7.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial. https://app.cochat.ai/papers/10.1097/wnf.0000000000000299
The paper
Miyaoka, T., Kanayama, M., Wake, R., Hashioka, S., Hayashida, M., Nagahama, M., Okazaki, S., Yamashita, S., Miura, S., Miki, H., Matsuda, H., Koike, M., Izuhara, M., Araki, T., Tsuchie, K., Azis, I. A., Arauchi, R., Abdullah, R. A., Oh-Nishi, A., & Horiguchi, J. (2018). Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.